

Resource Summary Report

Generated by [Kravitz](#) on Sep 18, 2026

Alzheimer's Research UK

RRID:SCR_003847

Type: Tool

Proper Citation

Alzheimer's Research UK (RRID:SCR_003847)

Resource Information

URL: <http://www.alzheimersresearchuk.org/>

Proper Citation: Alzheimer's Research UK (RRID:SCR_003847)

Description: The UK's leading dementia research charity that funds world-class, pioneering scientists at leading universities to find preventions, treatments and a cure for dementia.

Abbreviations: ARUK

Synonyms: Alzheimers Research UK

Resource Type: nonprofit organization

Keywords: late adult human, treat, prevent, alzheimer, dementia, portal, funding resource

Related Condition: Alzheimer's disease, Dementia

Resource Name: Alzheimer's Research UK

Resource ID: SCR_003847

Alternate IDs: ISNI: 0000 0000 9689 1581, Crossref funder ID: 501100002283, Wikidata: Q2840694, nlx_158161, grid.453466.6

Alternate URLs: <https://ror.org/02ymzm013>

Record Creation Time: 20220129T080221+0000

Record Last Update: 20260912T195603+0000

Ratings and Alerts

No rating or validation information has been found for Alzheimer's Research UK.

No alerts have been found for Alzheimer's Research UK.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 19 mentions in open access literature.

Listed below are recent publications. The full list is available at [Kravitz](#) .

Garg M, et al. (2025) Sex differences in cognitive decline and impairment: a scoping review in informatics literature. *Biology of sex differences*, 17(1), 11.

Watanabe A, et al. (2025) HAPLN2 forms aggregates and promotes microglial inflammation during brain aging in mice. *PLoS biology*, 23(8), e3003006.

Garg T, et al. (2024) The relationship between object-based spatial ability and virtual navigation performance. *PloS one*, 19(5), e0298116.

Zhu Y, et al. (2023) Developing an Instrument to Evaluate the Quality of Dementia Websites. *Healthcare (Basel, Switzerland)*, 11(24).

Tsalenchuk M, et al. (2023) Linking environmental risk factors with epigenetic mechanisms in Parkinson's disease. *NPJ Parkinson's disease*, 9(1), 123.

Chatterjee S, et al. (2023) Age-related changes in tau and autophagy in human brain in the absence of neurodegeneration. *PloS one*, 18(1), e0262792.

Soliman MG, et al. (2022) Development of amyloid beta gold nanorod aggregates as optoacoustic probes. *PloS one*, 17(3), e0259608.

de la Fuente J, et al. (2022) Integrated analysis of direct and proxy genome wide association studies highlights polygenicity of Alzheimer's disease outside of the APOE region. *PLoS genetics*, 18(6), e1010208.

Cannavo C, et al. (2022) Endosomal structure and APP biology are not altered in a preclinical mouse cellular model of Down syndrome. *PloS one*, 17(5), e0262558.

Åsenius F, et al. (2020) The DNA methylome of human sperm is distinct from blood with little evidence for tissue-consistent obesity associations. *PLoS genetics*, 16(10), e1009035.

Morgan BP, et al. (2018) Complement in the pathogenesis of Alzheimer's disease. *Seminars in immunopathology*, 40(1), 113.

Zeestraten EA, et al. (2016) Application of Diffusion Tensor Imaging Parameters to Detect Change in Longitudinal Studies in Cerebral Small Vessel Disease. PloS one, 11(1), e0147836.

Lourida I, et al. (2015) Parathyroid hormone, cognitive function and dementia: a systematic review. PloS one, 10(5), e0127574.

Tarczyluk MA, et al. (2015) Amyloid β 1-42 induces hypometabolism in human stem cell-derived neuron and astrocyte networks. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 35(8), 1348.

Lawrence AJ, et al. (2015) Pattern and Rate of Cognitive Decline in Cerebral Small Vessel Disease: A Prospective Study. PloS one, 10(8), e0135523.

Khabirova E, et al. (2014) The TRiC/CCT chaperone is implicated in Alzheimer's disease based on patient GWAS and an RNAi screen in A β -expressing *Caenorhabditis elegans*. PloS one, 9(7), e102985.

Izzo NJ, et al. (2014) Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate A β 42 oligomer binding and synaptotoxicity. PloS one, 9(11), e111899.

Hopkins PC, et al. (2013) Neurodegeneration in a *Drosophila* model for the function of TMCC2, an amyloid protein precursor-interacting and apolipoprotein E-binding protein. PloS one, 8(2), e55810.

Andrews KA, et al. (2013) Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials. PloS one, 8(3), e58816.